About
Explore non-pharmacological treatments that have historically offered promising results for managing migraines and the contemporary research supporting them. This session delves into innovative approaches like neuromodulation, nutraceuticals and mindfulness practices, providing a comprehensive look at alternative options to medication. Learn how to incorporate these methods into a migraine management toolbox for improved patient outcomes.
When
Tuesday, November 12, 2024 · 11:00 a.m. Eastern Time (US & Canada) (GMT -5:00)
Agenda
  • Neuromodulation - Presented by Professor Amaal Starling, Mayo Clinic, Phoenix, Arizona, USA
  • Nutraceuticals - Presented by Professor Marco Lisiki, IMMF, Cordoba, Argentina
  • Mindfulness - Presented by Professor David Seminowicz, University of Western Ontario, Canada
Presenters
1727277983-1bbe1ca20bfe5be0
Dr. Stephen Shrewsbury
Principal at Shrewd Consulting LLC and previously Chief Medical Officer at Impel Pharmaceuticals and at MAP Pharmaceuticals, and editor of Migraine Pain Management
Stephen B. Shrewsbury, spent his first 13 years in UK clinical practice in primary care and pulmonary medicine, before joining Glaxo and accepting honorary clinical positions at both the Department of Child Health at Southampton University and then the Department of Allergy and Clinical Immunology at the National Heart and Lung Institute in London. In 2000, he moved to the US and led Glaxo’s inhaled fluticasone and Upper Respiratory Inflammatory Disorders programs before moving to the west coast to lead Chiron’s Inhaled Antibiotic Core Team. Steve has held the CMO position in several biotech companies including MAP Pharmaceuticals, Adamas Pharmaceuticals, AVI BioPharma (now Sarepta Therapeutics), Aquinox Pharmaceuticals, and lastly at Impel Pharmaceuticals where he led drug-device combination product programs delivering drugs to the upper nasal space, in migraine, acute agitation and Parkinson’s disease and now runs his Shrewd Consulting business. Dr. Shrewsbury qualified MB ChB in Medicine from The University of Liverpool, UK.
1727278140-f1a53b0e58d176db
Dr. Amaal Starling
Professor, Mayo Clinic, Phoenix, Arizona, USA
Dr. Amaal J. Starling is an Associate Professor of Neurology in the Mayo Clinic College of Medicine and Science. She joined Mayo in 2012 and is currently a board-certified Consultant within the Department of Neurology. She is presently the Program Director for the Headache Medicine Fellowship and is Program Director for the Transitional Year Residency Program in the Mayo Clinic College of Medicine and Science – Arizona Campus.

Dr. Starling received her M.D. degree from Drexel University College of Medicine in Philadelphia. She completed a Transitional Year Residency, a Neurology Residency, and a Headache Fellowship at the Mayo Clinic College of Medicine in Scottsdale, Arizona. She was also the External Chief Resident for the Department of Neurology, Mayo Clinic, Arizona.

She is a Fellow of the American Academy of Neurology (AAN) and the American Headache Society (AHS). She is an active member American Medical Association and the American Pain Society. Dr. Starling serves on the advisory boards of Alder, AMGEN, Eli Lilly and Company, the International Concussion Society (ICS), NeurologyLive, the NDPH Research Foundation, and the United Council for Neurologic Subspecialties. In addition, she has served as the Co-Chair of the American Headache and Migraine Association, Chair of the New Investigator and Trainee Special Interest Section of the AHS. She has been an invited speaker to many international, national, and regional meetings and has been a perennial speaker at the AHS Annual Meeting in Scottsdale, Arizona. Her many honors include the AHS Above and Beyond Award for Service, Manfred D. Muenter Award for Excellence in Clinical Neurology, the AAN Annual Meeting Residency Scholarship, the 2012 Spirit of Mayo Clinic Award, and the Mayo Brothers Distinguished Fellowship Award. Dr. Starling’s most recent accolades include the Women Leading in Neurology recognition from the AAN, Super Supporter Award from Miles for Migraine, and the Outstanding Emerging Educator from the Mayo Clinic College of Medicine and Science.

Dr. Starling has over 70 peer-reviewed publications and abstracts related to her fields of interest which include migraine, concussion, posttraumatic headache, trigeminal autonomic cephalalgias, secondary headaches, telemedicine and teleconcussion, neurology resident education, and professionalism and clinical ethics. She is an active participant and member of many educational and departmental committees within Mayo Clinic.
1727278839-e8438c278356ca34
Dr. Marco Lisiki
Director, Headache Research Laboratory, Mercedes & Martín Ferreyra Institute – National Scientific and Technical Research Council (CONICET) – National University of Córdoba, Argentina
Marco Lisicki completed his medical and neurology training in Argentina before moving to Liège, Belgium, where he pursued a PhD under the supervision of Professor Jean Schoenen. Additionally, he holds a Master's degree in Headache Disorders from the University of Copenhagen, Denmark.

Dr. Lisicki is an active member and former Board member of the International Headache Society, currently serving on the Scientific, Education, and Membership Committees.

His research interests focus on the pathophysiology of headache, particularly electrophysiology, and the burden of headache disorders. Dr. Lisicki has been recognized for his contributions with several prestigious awards, including the Enrico Greppi Award (Italian Society for the Study of Headache, endorsed by the European Headache Federation), the Jorge Leston Award (Latin America Regional Headache Conference, endorsed by the International Headache Society), the Edgard Raffaelli Junior and Eliova Zukerman Awards (Brazilian Headache Society), and the Florencio Fiorini Award (endorsed by the Argentine National Academy of Medicine).
1727278730-a96bcbaec7b91e64
Dr. David Seminowicz
Professor, University of Western Ontario, Canada
Dr. Seminowicz earned a BSc from the University of Guelph, a PhD at the University of Toronto and completed postdoctoral training at McGill University. He was faculty at University of Maryland, Baltimore, 2010-2022, Principal Research Scientist at Neuroscience Research Australia, in Sydney, 2019-2022, and joined Western in 2022. His work focuses on the cognitive aspects of pain, individual differences in the response to pain, and the consequence of chronic pain on brain structure and function. His studies have clarified how pain-related and cognitive-related brain activity interact and how passive and active pain coping strategies affect these types of activity. His work further suggested a brain mechanism through which chronic pain might affect cognitive ability and continues testing this hypothesis in intervention studies in people with chronic pain. The clinical populations in these studies include chronic low back pain, chronic and episodic migraine, and burning mouth syndrome. Dr. Seminowicz has also used rodent MRI to ask a question that could not easily be addressed in humans, such as how the brain changes over time from before the onset of an injury that leads to chronic pain to the time when the disease affects cognitive and affective behaviors. Ongoing studies in Dr. Seminowicz’s lab employ longitudinal designs to assess how interventions affect brain function and whether pain biomarkers can be developed. Another line of work examines the role of the claustrum in cognitive control and pain. The main techniques in his lab include quantitative sensory testing, EEG, structural and functional MRI, and simultaneous EEG-fMRI. His main funding has been from the NIH, intercampus initiatives, private foundations, and industry.
Reserve Your Spot
Full name*
Email Address*
Job Title*
Institution*
Country*
Contact Permission
We would like to keep you up-to-date with what's happening at Elsevier and tell you about our latest products and other services. We may email you about information we think you'll be interested in, including reminders about upcoming events.
For more information, please read our privacy policy
✓ If you do not wish to receive such information please tick the box to opt out of these emails.